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  F
alciparum malaria kills, and it 
particularly kills the rural poor. 
Artemisinin derivatives, such 
as artesunate, are a vital component 
of   Plasmodium falciparum   malaria 
treatment and control in the face of 
globally increasing antimalarial drug 
resistance. Since 1998 a worsening 
epidemic of sophisticated counterfeit 
“artesunate” tablets (containing no 
artesunate) has plagued mainland 
Southeast Asia (see Figure S1). In 
some countries, most of the available 
artesunate is fake [1–5].
    Artemisinin derivatives are 
remarkably rapid in their antimalarial 
effects, and they are very well tolerated. 
So where these medicines are available, 
they are sought after. But as they 
are relatively expensive, a demand is 
created for cheaper versions amongst 
the poorest and most vulnerable 
people, upon whom the counterfeiters 
have preyed–with fatal results. 
    Documented Death due to Fake 
Artesunate
    The death of patients with untreated 
falciparum malaria, as a result of 
unwittingly taking fake artesunate, 
is hidden in the inadequately 
documented mortality statistics of the 
relatively voiceless rural poor. But there 
is no doubt that such deaths occur, and 
they are probably common. 
    In February 2005, a 23-year-old 
man presented with fever to a rural 
hospital in eastern Burma where he was 
diagnosed as having uncomplicated 
hyperparasitaemic falciparum malaria 
by microscopy (4.2% infected red 
blood cells). He was treated with oral 
artesunate, labelled as made by Guilin 
Pharmaceutical (Guangxi, People’s 
Republic of China), 4 mg/kg once a 
day, the treatment of choice in this 
area. Since artemisinin derivatives 
have been used in this area, not one 
of 600 patients prospectively studied 
with ≥4% parasitaemia has died [6]. 
However, on the third night the young 
Burmese man became unconscious 
and was transferred to another hospital 
where he was found to be in a coma 
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  Figure 1.   Genuine (Left) and Counterfeit (Right) Cotexcin (Dihydroartemisinin) from Tanzania 
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(Glasgow Coma Score = 3/15), with 
renal failure and a higher parasitaemia 
(5.5% infected red blood cells). He was 
perfused with intravenous ﬂ  uids and 
received an injection of intravenous 
artesunate (2.4 mg/kg) and transferred 
to a third hospital where he died 
within 12 hours of arrival from cerebral 
malaria. 
    The original hospital sent the 
artesunate used to treat the patient 
for analysis by the Fast Red dye test 
[7]. We found that the artesunate was 
counterfeit. Based on the appearance 
of the counterfeit hologram afﬁ  xed 
to the blister pack, it was identiﬁ  ed 
as a Type 9 counterfeit artesunate 
(see Figure S1). Accurate mass 
measurements by direct time-of-ﬂ  ight 
mass spectrometry [8] revealed that the 
main active ingredient in this “drug” 
was paracetamol (acetaminophen), but 
that artesunate was also present in the 
tablet [9]. Quantiﬁ  cation using high-
performance liquid chromatography 
determined that the artesunate content 
was 10 mg per tablet, instead of the 
~50 mg of artesunate present in the 
genuine product [9]. 
    The hospital where he was originally 
treated had, in good faith, recently 
purchased a large quantity of 
artesunate tablets. They were dismayed 
to learn from this death that their 
entire stock was fake. The village 
committee, which now had a clear 
idea of what was responsible for the 
man’s death, was so angered by this 
avoidable death that they collected 
all the artesunate, fake and genuine, 
that they could ﬁ  nd in local shops and 
destroyed it on a public bonﬁ  re in front 
of the whole village, to stress the lethal 
dangers of fake antimalarials.
    The Epidemic of Counterfeit 
Artesunate in Southeast Asia
    Counterfeit artesunate continues to 
circulate on a vast scale in mainland 
Southeast Asia, where between 38% 
and 52% of “artesunate” blister 
packs sampled contain no active 
ingredient [1–5]. So far, only the Guilin 
Pharmaceutical brand of artesunate 
has been counterfeited. We make 
no apology for the use of the term 
  manslaughter   to describe this criminal 
lethal trade. Indeed, some might 
call it murder. Somewhere, people 
are directing a highly technical and 
sophisticated criminal trade. They are 
making tablets out of starch, chalk, and 
a variety of wrong active ingredients, 
such as erythromycin [9,10], for a life-
threatening disease that particularly 
affects the poor and underprivileged. 
The criminals are making these fakes in 
the full knowledge that their ineffective 
product might kill people who would 
otherwise survive their malaria infection. 
    There are now at least 12 different 
types of fake artesunate, classiﬁ  ed by 
the sophisticated counterfeit holograms 
that are afﬁ  xed to the blister packs 
(see Figure S1). Evidence suggests that 
production is on an industrial scale 
and from multiple sources; 100,000 
counterfeit artesunate tablets were 
purchased from one large pharmacy [2].
    This epidemic of a counterfeit, 
vital, life-saving medicine has received 
little practical attention over the last 
eight years, in comparison with the 
considerable efforts in other aspects of 
malaria control [3,11]. In addition to 
unnecessary loss of life for proﬁ  t, it has 
led to a loss of conﬁ  dence in these very 
effective medicines and given rise to 
false reports of artemisinin resistance 
[1,12]. Much more needs to be done in 
Asia to combat this scourge.
    The Risk to Western Travellers
    This criminal activity is unlikely to 
remain a local difﬁ  culty, and there 
are serious implications from this 
major public health problem for the 
wider world beyond Asia that deserve 
attention. In the industrialised North, 
with carefully regulated trade, the 
implications are limited. However, 
especially as the artemisinin derivatives 
have a natural plant origin, tourists 
commonly buy them in the tropics 
as a standby treatment [13]. Indeed, 
Web sites encourage this practice [14], 
which is likely to be compounded 
by the availability of artemisinin 
derivatives on the Internet [15]. It is 
inevitable that counterfeit artesunate 
will seep into this trade. 
    We suggest that travel clinics should 
warn those going to the tropics of the 
potential dangers of buying such drugs. 
Unfortunately, in our discriminatory 
world, the unnecessary death of a 
tourist, journalist, or of a diplomat or 
military personnel, from a wealthy, 
inﬂ  uential country after self-medicating 
with fake artesunate, may be required 
to trigger the political will required to 
eradicate this lethal trade.
    Will Africa Be Next?
    Of far greater concern is that 
counterfeits may follow in the wake 
of the genuine artesunate that is 
increasingly being imported for use in 
sub-Saharan Africa, where the burden 
of malaria is greatest. Since 2001, 
the World Health Organisation has 
recommended that malaria-endemic 
African countries should consider 
changing to artemisinin derivative– 
based combination therapy (ACT) as 
ﬁ  rst-line malaria treatment. In the past 
two years, most countries in Africa (34 
in 2004) have made this change [16]. 
Implementing this new policy will 
not be easy because of the high cost 
of ACTs and a temporary shortage of 
the plant raw material. It is estimated 
that 130 million courses of ACT will 
be used in Africa in 2006 [16]. High 
cost and shortage of ACT provide a 
favourable situation for the spread of 
fake artemisinins that could put the 
lives of thousands of African children 
DOI: 10.1371/journal.pmed.0030197.g002 
  Figure 2.   Genuine (Right) and Counterfeit (Left) Arsumax (Artesunate) from Cameroon 
(Photograph by Manuela Sunjio)
      Note that the genuine Arsumax bears a hologram from Guilin Pharmaceutical, which manufactures 
the tablets (see Figure S1). 
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at risk. There is already a thriving fake 
antimalarial drug industry in Africa 
[17], suggesting that it is highly likely 
that counterfeit artesunate or ACTs 
will follow in the wake of the genuine 
products, and in bulk. 
    Counterfeit dihydroartemisinin (60 
mg per tablet; Cotexcin) was reported 
from Tanzania in 2001 [18], labelled 
as made by Beijing COTEC New 
Technology Corp, and containing no 
dihydroartemisinin or other active 
drug when analysed by thin layer 
chromatography and high-performance 
liquid chromatography (Figure 1, 
collection and analysis of the sample by 
MS, CB, and PM). In 2005, counterfeit 
artesunate tablets, mimicking Arsumax 
(50 mg per tablet; Sanoﬁ   Synthelabo, 
Bridgewater, New Jersey, United States) 
were found in Cameroon (Figure 2, 
collection and analysis of the sample by 
MS, CB, and PM). These were labelled 
as Arsuman manufactured by Sanoﬁ   
Synthelabo, who conﬁ  rmed that the 
packaging was counterfeit. On high-
performance liquid chromatography 
analysis, these tablets did contain 50 
mg of artesunate (MS, CB, PM), and 
this counterfeit is a look-alike copy 
of the genuine product. That at least 
two different counterfeit artemisinin 
derivatives have already been 
distributed in Africa is of considerable 
concern. Because of inadequate systems 
for the monitoring of the quality of 
antimalarial medicines, and because 
few have looked for it, counterfeit 
artesunate may already be widespread.
    It is likely that, initially, most ACTs 
in Africa will be provided through the 
public health system where it should 
be relatively easy to control quality 
by purchasing only from established 
companies or from an international 
purchasing facility and by providing 
strong support to national quality 
control laboratories. However, the 
possibility of corruption within the 
national purchasing process cannot be 
excluded, as the potential ﬁ  nancial gains 
for those involved could be very high. 
    In many parts of Africa, most 
patients with uncomplicated malaria 
obtain treatment from the private 
sector. Provision of free, or heavily 
subsidised, highly effective ACTs 
through public health facilities may 
reduce this proportion. However, it is 
likely that for the foreseeable future a 
substantial proportion of antimalarials 
used in Africa will be obtained through 
the private sector and it is here that 
the danger from fake artemisinins 
is greatest. Ofﬁ  cial promotional 
campaigns are likely to create immense 
demand for ACTs through the private 
system even though many potential 
users will struggle to meet their cost. 
In such a situation, introduction of a 
relatively inexpensive fake ACT product 
could lead to widespread usage of the 
fake drug with disastrous consequences.
    Preventing an Epidemic of Fake 
Artesunate in Africa
    How might the spread of fake 
artesunate be prevented? Control of 
medicine importation is a ﬁ  rst barrier 
of defence, but this is difﬁ  cult to 
maintain and antimalarials are readily 
shipped across porous frontiers. 
There are at least 11 different brands 
of oral artesunate available in sub-
Saharan Africa, including the genuine 
Guilin Pharmaceutical product. One 
of the authors was recently offered 
seven different artemisinin derivative 
brands in one small-town West African 
pharmacy—it is unlikely that all of 
these had been imported through 
ofﬁ  cial channels. 
    A second more radical option is to 
ensure that ACTs provided through 
the private sector are relatively 
inexpensive and locally affordable so 
that there is no ﬁ  nancial advantage 
to looking elsewhere and thereby 
unwittingly purchasing a fake. This 
would require some form of central 
subsidy, as recently suggested in an 
Institute of Medicine (Washington 
D. C., United States) report [19]. 
This recommendation was made 
primarily to increase access to ACTs 
and to discourage monotherapy with 
artemisinins or the partner medicine 
(the co-drug in ACT) and thus to 
protect the ACT from the emergence 
of resistant parasites. Such an 
approach would have the additional 
advantage of discouraging the use of 
fake artemisinin-based medicines, as 
the counterfeit manufacturers would 
have little margin to make a proﬁ  t. We 
strongly suggest that African countries 
and health organisations support such 
strategies to try to prevent counterfeit 
artemisinins from infecting Africa, to 
establish effective systems to carefully 
monitor their antimalarial drug supply, 
and to prepare to counter a problem 
that, as is evident from Asia, is very 
difﬁ  cult to eradicate once established.  
    Of global concern for the future 
of malaria control, some counterfeit 
artesunate samples (Types 4, 10, 
and 11) recently collected in eastern 
Burma do contain small subtherapeutic 
quantities of artesunate (3.5–12.1 
mg/tablet [9]).   P. falciparum   parasites 
with stable in vivo resistance to the 
artemisinin derivatives have not yet 
been described from the wild, but 
parasites with reduced in vitro sensitivity 
to artemether have recently been 
reported [20]. The in vivo exposure 
of parasites to low concentrations of 
artesunate from fake products will 
greatly increase the risk of the selection 
and spread of artemisinin resistant 
parasites, leading to the catastrophic 
loss of these essential medicines and 
an entirely avoidable failure of malaria 
control. We cannot afford to lose these 
drugs, as we have lost chloroquine and 
sulphadoxine–pyrimethamine—most 
current combinations depend on ACTs. 
In addition, the presence of small 
quantities of artesunate in tablets may 
mean that the Fast Red dye test [7], 
widely used for screening the quality 
of artesunate tablets, may give false 
positive results depending on how 
much artesunate is present in these 
fakes.
  Conclusion
    Fake artesunate could compromise 
the hope that ACT therapy offers for 
malaria control in Africa and Asia. 
Fakes containing subtherapeutic 
amounts of artesunate could also 
result in the emergence and spread 
of resistance to the artemisinin drugs, 
shortening the useful life of these vital 
medicines. But this tragedy is avoidable, 
if there is sufﬁ  cient political will. As 
global efforts to control malaria rely 
heavily on these drugs, these issues 
deserve overdue, urgent action to 
prevent a public health disaster in the 
malarious world.  
  Supporting  Information
      Figure S1.   Fake Artesunate Warning Sheet 
Number 4, April 2006 
    At least 12 different types of fake artesunate 
are being sold in mainland Southeast Asia. 
This warning sheet gives some key features 
to aid identiﬁ  cation of these fakes.
    Found at DOI: 10.1371/journal.
pmed.0030197.sg001 (1.1 MB PDF). 
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